NEW YORK (GenomeWeb News) – Stocks for 'omics tools and molecular diagnostics firms climbed in September amid a general upswing for biotech stocks.
Among the 30 firms that comprise the GenomeWeb Daily News Index, only four saw a decline in their share price over the course of the month, and not a single stock was down in the double digits.
The highest percentage gainer for September was Rosetta Genomics, which was up around 34 percent. The firm's shares have been fairly volatile over the past few months and have traded as low as $3.88 on Aug. 17 and as high as $12.87 on July 3. Though it closed Friday at $7.19, the stock was down 10 percent in Monday afternoon trade at $6.50 after Rosetta reported a decline in first-half revenues.
Among the four firms to lose ground for the month Cepheid's shares fell furthest, down nearly 9 percent. Its month-to-month drop was due to an announcement late last week that the firm would miss revenue estimates for the third quarter due to interruption in supply of a part for its Xpert cartridges. Cepheid noted a day later at its analyst day that it plans to acquire a plastics firm that would make the molding for the cartridges.
In addition to Cepheid, Pacific Biosciences (-7 percent), Sequenom (-4 percent), and Vermillion (-2 percent) were the other decliners.
Overall, the GWDN Index was up nearly 4.4 percent, compared to the Nasdaq Biotech Index, which jumped 4.9 percent. The broader Nasdaq was up 1.6 percent and the Dow Jones Industrial Average climbed 2.6 percent.
During the month, four of the firms in in the GWDN Index paid out dividends — Agilent ($.10 on Sept. 28); Becton Dickinson ($.45 on Sept. 5); Danaher ($.025 on Sept. 26); and Thermo Fisher Scientific ($.13 on Sept. 13). Adjusting for those dividends, the Index was up slightly more than 4.4 percent.